Mayrim V Rios Perez
Overview
Explore the profile of Mayrim V Rios Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roife D, Dai B, Kang Y, Rios Perez M, Pratt M, Li X, et al.
Clin Cancer Res
. 2024 Jul;
30(13):2846.
PMID: 38946291
No abstract available.
2.
Capello M, Fahrmann J, Rios Perez M, Vykoukal J, Irajizad E, Tripathi S, et al.
JCO Precis Oncol
. 2022 Jan;
4:426-436.
PMID: 35050739
Purpose: The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role for the serine hydrolase...
3.
Chen Y, Capello M, Rios Perez M, Vykoukal J, Roife D, Kang Y, et al.
Mol Metab
. 2021 Dec;
56:101426.
PMID: 34971802
Objective: Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2) contributes to the activation of the pro-drug irinotecan in pancreatic ductal adenocarcinoma (PDAC). Given other potential roles of CES2, we...
4.
Rios Perez M, Roife D, Dai B, Pratt M, Dobrowolski R, Kang Y, et al.
Surg Open Sci
. 2021 May;
1(2):56-63.
PMID: 33981979
Background: Auranofin, a Food and Drug Administration-approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent...
5.
Koay E, Lee Y, Cristini V, Lowengrub J, Kang Y, San Lucas F, et al.
Clin Cancer Res
. 2018 Aug;
24(23):5883-5894.
PMID: 30082477
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with variable presentations and natural histories of disease. We hypothesized that different morphologic characteristics of PDAC tumors on diagnostic computed tomography...
6.
Ivanics T, Bergquist J, Liu G, Kim M, Kang Y, Katz M, et al.
Lab Invest
. 2018 Mar;
98(7):947-956.
PMID: 29520054
Patient-derived xenografts (PDX) are being increasingly utilized in preclinical oncologic research. Maintaining large colonies of early generation tumor-bearing mice is impractical and cost-prohibitive. Optimal methods for efficient long-term cryopreservation and...
7.
Dai B, Roife D, Kang Y, Gumin J, Rios Perez M, Li X, et al.
Mol Cancer Ther
. 2017 Feb;
16(4):662-670.
PMID: 28138026
Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In a phase I clinical trial, Delta-24-RGD has...
8.
Roife D, Dai B, Kang Y, Rios Perez M, Pratt M, Li X, et al.
Clin Cancer Res
. 2016 Jun;
22(24):6021-6030.
PMID: 27259561
Purpose: Translation of the patient-derived xenograft (PDX) model into a method for practical personalized cancer treatment is prevented by the intense resources and time necessary to generate and test each...
9.
Kang Y, Roife D, Lee Y, Lv H, Suzuki R, Ling J, et al.
Clin Cancer Res
. 2016 Apr;
22(19):4934-4946.
PMID: 27126993
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within...
10.
Rios Perez M, Dai B, Koay E, Wolff R, Fleming J
Cureus
. 2016 Feb;
7(12):e423.
PMID: 26848412
Although data suggests little hope for survival when patients present with metastatic pancreatic cancer, recent advances in systemic therapy offer the possibility for dramatic tumor responses like those observed in...